At a glance
- Originator Nonindustrial source
- Class Antiasthmatics; Bronchodilators; Muscle relaxants
- Mechanism of Action Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 20 Jun 2001 No-Development-Reported for Asthma in European Union (Unknown route)
- 07 Mar 1997 Novartis is developing SCA 40 in the European Union
- 09 Feb 1996 Preclinical development for Asthma in European Union (Unknown route)